Glatiramer acetate protects against inflammatory synaptopathy in experimental autoimmune encephalomyelitis

Journal of Neuroimmune Pharmacology

Volumn 8, Issue 3, 2013, Pages 651-663

  Gentile, Antonietta ^a,b   Rossi, Silvia ^a,b   Studer, Valeria ^a,b   Motta, Caterina ^a,b   De Chiara, Valentina ^a,b   Musella, Alessandra ^a,b   Sepman, Helena ^a   Fresegna, Diego ^a,b   Musumeci, Gabriele ^a   Grasselli, Giorgio ^a,d   Haji, Nabila ^a,c   Weiss, Sagit ^e   Hayardeny, Liat ^e   Mandolesi, Georgia ^a   Centonze, Diego ^a,b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF CHICAGO   (United States)

^e TEVA PHARMACEUTICALS   (Israel)

Author keywords

EAE; EPSC; GA; Microglia; Striatum; TNF

Indexed keywords

GLATIRAMER; GLUTAMIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; BRAIN SLICE; CELL ACTIVATION; CELL STIMULATION; CONTROLLED STUDY; CORPUS STRIATUM; CYTOKINE RELEASE; DRUG EFFECT; DRUG TREATMENT FAILURE; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; GRAY MATTER; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; MICROGLIA; MICROSCOPY; MOUSE; MULTIPLE SCLEROSIS; NERVE CELL; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELLS, CULTURED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PEPTIDES; SYNAPSES;

EID: 84878799198     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-013-9436-x     Document Type: Article

References (45)

1. Aharoni R, Teitelbaum D, Sela M, Arnon R (1997) Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 94:10821-10826
2. Aharoni R, Arnon R, Eilam R (2005a) Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J Neurosci 25:8217-8228
3. Aharoni R, Eilam R, Domev H, Labunskay G, Sela M, Arnon R (2005b) The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A 102:19045-19050
4. Aharoni R, Vainshtein A, Stock A, Eilam R, From R, Shinder V, Arnon R (2011) Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate. J Autoimmun 37:228-241
5. Arnon R, Aharoni R (2004) Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A 101:14593-14598
6. Arnon R, Aharoni R (2007) Neurogenesis and neuroprotection in the CNS-fundamental elements in the effect of glatiramer acetate on treatment of auroimmune neurological disorders. Mol Neurobiol 36:245-253
7. Azoulay D, Vachapova V, Shihman B, Miler A, Karni A (2005) Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol 167:215-218
8. Bakshi R, Benedict RH, Bermel RA, Caruthers SD, Puli SR, Tjoa CW, Fabiano AJ, Jacobs L (2002) T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 59:62-68
9. Bermel RA, Innus MD, Tjoa CW, Bakshi R (2003) Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study. Neuroreport 14:335-339
10. Blair M, Pease ME, Hammond J, Valenta D, Kielczewski J, Levkovitch-Verbin H, Quigley H (2005) Effect of glatiramer acetate on primary and secondary degeneration of retinal ganglion cells in the rat. Invest Ophthalmol Vis Sci 46(3):884-890
11. Bolton C, Paul C (1997) MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. J Pharmacol Exp Ther 282:397-402
12. Boster A, Bartoszek MP, O'Connell C, Pitt D, Racke M (2011) Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 4:319-332
13. Caragnano M, Tortorella P, Bergami A, Ruggieri M, Livrea P, Specchio LM, Martino G, Trojano M, Furlan R, Avolio C (2012) Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis. J Neuroimmunol 245(1-2):93-97
14. Centonze D, Muzio L, Rossi S, Cavasinni F, De Chiara V, Bergami A, Musella A, D'Amelio M, Cavallucci V, Martorana A, Bergamaschi A, Cencioni MT, Diamantini A, Butti E, Comi G, Bernardi G, Cecconi F, Battistini L, Furlan R, Martino G (2009) Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci 29:3442-3452
15. Chabot S, Williams G, Yong VW (1997) Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b. J Clin Invest 100:604-612
16. Chabot S, Yong FP, Le DM, Metz LM, Myles T, Yong VW (2002) Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis. Mult Scler 8:299-306
17. Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M (2011) Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol 69:75-82
18. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502-1517
19. Dupuis M, De Jesús Ibarra-Sánchez M, Tremblay ML, Duplay P (2003) Gr-1+ myeloid cells lacking T cell protein tyrosine phosphatase inhibit lymphocyte proliferation by an IFN-gamma- and nitric oxide-dependent mechanism. J Immunol 171:726-732
20. Fridkis-Hareli M, Teitelbaum D, Pecht I, Arnon R, Sela M (1997) Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells. Int Immunol 9:925-934
21. Geurts JJ, Barkhof F (2008) Grey matter pathology in multiple sclerosis. Lancet Neurol 7:841-851
22. Gonsette RE (2008) Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci 274:48-53
23. Haji N, Mandolesi G, Gentile A, Sacchetti L, Fresegna D, Rossi S, Musella A, Sepman H, Motta C, Studer V, De Chiara V, Bernardi G, Strata P, Centonze D (2012) TNF-α-mediated anxiety in a mouse model of multiple sclerosis. Exp Neurol 237(2):296-303
24. Heppner FL, Greter M, Marino D, Falsig J, Raivich G, Hövelmeyer N, Waisman A, Rülicke T, Prinz M, Priller J, Becher B, Aguzzi A (2005) Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 11:146-152
25. Herrmann AM, Göbel K, Simon OJ, Melzer N, Schuhmann MK, Stenner MP, Weishaupt A, Kleinschnitz C, Bittner S, Meuth P, Stuve O, Budde T, Kieseier BC, Wiendl H, Meuth SG (2010) Glatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell death. Am J Pathol 177:3051-3060
26. Hong J, Li N, Zhang X, Zheng B, Zhang JZ (2005) Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci U S A 102:6449-6454
27. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268-1276
28. Kala M, Miravalle A, Vollmer T (2011) Recent insights into the mechanism of action of glatiramer acetate. J Neuroimmunol 235:9-17
29. Kim HJ, Ifergan I, Antel JP, Seguin R, Duddy M, Lapierre Y, Jalili F, Bar-Or A (2004) Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 172:7144-7153
30. Liu J, Johnson TV, Lin J, Ramirez SH, Bronich TK, Caplan S, Persidsky Y, Gendelman HE, Kipnis J (2007) T cell independent mechanism for copolymer-1-induced neuroprotection. Eur J Immunol 37:3143-3154
31. Lynch MA (2009) The multifaceted profile of activated microglia. Mol Neurobiol 40:139-156
32. Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S, Lahat N (1998) Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 92:113-121
33. Muzio L, Martino G, Furlan R (2007) Multifaceted aspects of inflammation in multiple sclerosis: the role of microglia. J Neuroimmunol 191:39-44
34. Pitt D, Werner P, Raine CS (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6:67-70
35. Ponomarev ED, Shriver LP, Maresz K, Dittel BN (2005) Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. Neurosci Res 81:374-389
36. Pul R, Moharregh-Khiabani D, Škuljec J, Skripuletz T, Garde N, Voss EV, Stangel M (2011) Glatiramer acetate modulates TNF-α and IL-10 secretion in microglia and promotes their phagocytic activity. J Neuroimmune Pharmacol 6:381-388
37. Ratchford JN, Endres CJ, Hammoud DA, Pomper MG, Shiee N, McGready J, Pham DL, Calabresi PA (2012) Decreased microglial activation in MS patients treated with glatiramer acetate. J Neurol 259:1199-1205
38. Rossi S, Furlan R, De Chiara V, Muzio L, Musella A, Motta C, Studer V, Cavasinni F, Bernardi G, Martino G, Cravatt BF, Lutz B, Maccarrone M, Centonze D (2011a) Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis. Brain Behav Immun 25:1242-1248
39. Rossi S, Muzio L, De Chiara V, Grasselli G, Musella A, Musumeci G, Mandolesi G, De Ceglia R, Maida S, Biffi E, Pedrocchi A, Menegon A, Bernardi G, Furlan R, Martino G, Centonze D (2011b) Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis. Brain Behav Immun 25:947-956
40. Rossi S, Furlan R, De Chiara V, Motta C, Studer V, Mori F, Musella A, Bergami A, Muzio L, Bernardi G, Battistini L, Martino G, Centonze D (2012) Interleukin-1β causes synaptic hyperexcitability in multiple sclerosis. Ann Neurol 71:76-83
41. Sanna A, Fois ML, Arru G, Huang Y-M, Link H, Pugliatti M, Rosati G, Sotgiu S (2006) Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin Exp Immunol 143:357-362
42. Saresella M, Marventano I, Longhi R, Lissoni F, Trabattoni D, Mendozzi L, Caputo D, Clerici M (2008) CD4+CD25+FoxP3+PD1 regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy. FASEB J 22:3500-3508
43. Schori H, Kipnis J, Yoles E, WoldeMussie E, Ruiz G, Wheeler LA, Schwartz M (2001) Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci U S A 98(6):3398-3403
44. Trapp BD, Nave KA (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31:247-269
45. Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, Lee L, Patarroyo JC, Stüve O, Sobel RA, Steinman L, Zamvil SS (2007) Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 13:935-943